Visudyne fails phase III trial for "occult" wet AMD (Age-related Macular Degeneration)
This article was originally published in Clinica
Executive Summary
The age-related macular degeneration (AMD) treatment Visudyne, developed by QLT, has failed to reduce the risk of vision loss after two years in a subgroup of patients with the wet form of the disease.